The proposed BioTester is an oracle-based automated testing framework that integrates retrieval-augmented LLMs with a differential testing strategy to address the long-standing oracle problem in bioinformatics software testing, demonstrating superior defect-detection performance over existing methods on the constructed benchmark.
Abstract
Abstract Bioinformatics software plays a critical role in clinical applications such as cancer screening and genetic disease diagnosis, where comprehensive quality management is essential for ensuring the accuracy and reliability of downstream analysis. However, current validation practices rely heavily on manually designed simulation experiments, which are labor-intensive and limited in their ability to systematically identify potential quality risks under certain scenarios. In this study, we first construct a benchmark by simulating subtle implementation-level defects in bioinformatics programs. We then propose BioTester, an oracle-based automated testing framework that integrates software testing techniques to support more comprehensive quality assessment of bioinformatics software. BioTester integrates retrieval-augmented LLMs with a differential testing strategy to address the long-standing oracle problem in bioinformatics software testing, demonstrating superior defect-detection performance over existing methods on the constructed benchmark. Finally, applying BioTester to real-world bioinformatics software demonstrates its practical effectiveness and highlights the value of automated testing as a generalizable complement to existing validation practices for improving software reliability in biomedical applications.
This work demonstrates that adopting MDSE principles provides a systematic methodology for transforming multifaceted clinical data into actionable medical insights and establishes a scalable architecture for high-quality, software-intensive systems in the healthcare domain.
A. Pérez-Gômez, Mireia Costa, A. García et al.· 0 citations
Background Phenotype-genotype associations underpin precision medicine by enabling disease prevention, early diagnosis, risk stratification, therapeutic target discovery, and personalized treatment. However, the rapid growth of scientific evidence has made manual curation of these associations increasingly labor-intens...
Caiwan Sun, Yi Xin, Sarah Zeng et al.· bioRxiv· 0 citations
Machine learning-based annotation methods are increasingly used to assess the pathogenicity of genetic variants, but their performance at prioritizing variants for gene-level association testing remains poorly characterized. Here, to better understand and optimize for this use case, we assess variant annotations from...
Matthew Aguirre, Flaviyan Jerome Irudayanathan, M. Crow et al.· BMC Genomics· 0 citations
One of the primary barriers to implementing next-generation sequencing (NGS) in clinical laboratories is the perceived need for a dedicated bioinformatician and/or costly commercial analysis software. As a result, many laboratories lack the flexibility to design, validate, and adapt NGS analysis workflows tailore...
Lucas J. Osborn, Chao Sun, Mihaela Campan· Clinical Chemistry· 0 citations
The selection of biomarker-specific patient populations is essential in targeted cancer therapies to enhance precision and efficacy. To ensure a successful launch, it is vital to promote awareness and adoption of biomarker testing at diagnosis, tailor implementation strategies to accommodate local variations, and ensur...
Dai Feng, Amber Lind, Weili He· Journal of Biopharmaceutical...· 0 citations
This study presents a comprehensive benchmark analysis of InheriNext®, a domain-specific, AI-powered tool designed for phenotype-driven pathogenic variant prioritization. For this study, 7,244 whole exome test cases were generated using phenotype and genotype data from Phenopackets, along with pools of variants from he...
Justin Chang, Kuan Li, Yu-Shen Tsai et al.· Journal of Advances in Artif...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.